Collagen V nasal tolerance in experimental model of systemic sclerosis.
Our aim was to study skin remodeling and autoantibody production in an experimental model of scleroderma (SSc), following nasal tolerance with human type V collagen (Col V). Female New Zealand rabbits (n = 12) were immunized with two doses of 1 mg/ml of Col V in complete Freund's adjuvant and additional two boosters in incomplete Freund's adjuvant to induce SSc. After 150 days, half of these immunized rabbits were submitted to type V collagen-induced tolerance receiving a daily nasal administration of 25 mug of Col V. Control animals (n = 6) were only submitted to type V collagen-induced tolerance. Serial skin biopsies were performed on days 0, 150 and 210, and stained with H&E, Masson's trichrome and Picrosirius for morphological and morphometric analysis. Types I, III and V collagen were identified by immunofluorescence. The animals' serum samples were collected to determine anti types I, III, IV and V collagen and antinuclear antibodies (ANA). Skin biopsies from immunized animals confirmed SSc morphology as previously described, such as progressive decrease of papillary dermis, appendages atrophy, increased type I, III and V collagen deposition. Rabbits with Col V-induced nasal tolerance showed reduction of skin involvement, with significant decrease of collagen amount. Humoral immune response did not change with nasal tolerance. Collagen V nasal tolerance promotes regression of skin remodeling process in an experimental model of SSc. We suggest that nasal tolerance with type V collagen can be a promising therapeutic option to treat scleroderma patients.
Velosa
Ana Paula Pereira
AP
Discipline of Reumatology, Faculty of Medicine, University of São Paulo, Av. Dr. Arnaldo 455; cep-01246-903, São Paulo, SP, Brazil.
Teodoro
Walcy Rosolia
WR
de Oliveira
Cristiane Carla
CC
Dos Santos Filho
Antonio
A
Moutinho
Rodnei Francisco
RF
Santos
Angela Gomes
AG
Vendramini
Margarete Borges Galhardo
MB
Bueno
Cleonice
C
Parra
Edwin Roger
ER
Capelozzi
Vera Luiza
VL
Yoshinari
Natalino Hajime
NH
D000281:Administration, Intranasal; D000818:Animals; D000906:Antibodies / Q000276:immunology / Q000378:metabolism; D000974:Antibodies, Antinuclear / Q000276:immunology / Q000378:metabolism; D001706:Biopsy; D003094:Collagen / Q000276:immunology / Q000378:metabolism; D024062:Collagen Type V / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use*; D004195:Disease Models, Animal; D005260:Female; D011817:Rabbits; D012595:Scleroderma, Systemic / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D012867:Skin / Q000378:metabolism / Q000473:pathology
D000906:Antibodies; D000974:Antibodies, Antinuclear; D024062:Collagen Type V; D003094:Collagen